The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug Transference in Pregnancy: RheumMadness 2022 TNFi in Cord Blood Scouting Report

Drug Transference in Pregnancy: RheumMadness 2022 TNFi in Cord Blood Scouting Report

March 2, 2022 • By University of Chicago Medicine: Lauren He, MD; & Cuoghi Edens, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The observation that detectable drug concentrations were measured in many of the samples is reason to pause and ask: What is the clinical significance of this finding?

You Might Also Like
  • Beyond Trial & Error: RheumMadness 2022 AI: TNFi Response Scouting Report
  • Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report
  • Regeneration: RheumMadness 2022 Axolotl Limbs Scouting Report
Explore This Issue
May 2022

The concentration ratio of TNF inhibitors in cord blood to maternal blood ranged from 0.01 to 0.062, depending on the agent, suggesting very low levels of transfer. The clinical significance of these levels of anti-TNF agents may not be fully established, but we have plenty of evidence to suggest the levels are safe. Studies have shown concentrations of 0.1 μg/mL can bind all circulating TNF, suggesting this level as a cutoff value for clinically relevant concentrations.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Infants born to mothers on anti-TNF therapy have been studied more extensively in inflammatory bowel disease (IBD) literature. Those studies have shown the use of biologic therapy during pregnancy does not affect infant response to vaccines or achievement of developmental milestones, or increase the risk of infection.4-6

Certolizumab is the anti-TNF treatment we all know and love because it’s safe during pregnancy. It’s known for its unique lack of immunoglobulin G (IgG) fragment crystallizable (Fc) region, which keeps it from binding to the placental Fc receptor and, thus, is not transferred across the placenta from mother to fetus.7 But what about etanercept? Previous studies suggest some transplacental transport via antibody Fc fragment, but our base article suggests a lack of significant placental transfer.8 Along with evidence suggesting little, if any, placental transfer during pregnancy when stopped prior to 30 weeks of gestation, this finding may elicit a stronger support for use of etanercept throughout pregnancy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR guideline is notably less specific than EULAR, grouping most TNF inhibitors—other than certolizumab—together into the same category, with the conditional recommendation to continue these treatments during the first and second trimesters and discontinue during the third trimester, several half-lives prior to delivery.9 Guidelines for pregnant patients with IBD on biologic therapy recommend continuing biologics throughout pregnancy without interruption.10 Instead of discontinuing therapy, providers typically adjust the final dosing prior to delivery to achieve a low estimated trough because this is associated with lower adverse pregnancy outcomes for both mother and baby.

Implications

The implications of this study for patients cannot be overstated. In this unique circumstance, in which providers are taking care of both the mother and baby, every decision matters. These results can help providers make specific, patient-centered recommendations for their patients when it comes to the use of TNF inhibitors during pregnancy. The methods used in this study serve as an example of how to further examine transference of biologics and other drugs from mother to fetus.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Drug Updates, Research Reviews Tagged With: cord blood, drug transference, pregnancy, RheumMadness, TNFi, tumor necrosis factor inhibitor (TNFi)Issue: May 2022

You Might Also Like:
  • Beyond Trial & Error: RheumMadness 2022 AI: TNFi Response Scouting Report
  • Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report
  • Regeneration: RheumMadness 2022 Axolotl Limbs Scouting Report
  • An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)